| Budget Amount *help |
¥218,010,000 (Direct Cost: ¥167,700,000、Indirect Cost: ¥50,310,000)
Fiscal Year 2016: ¥39,650,000 (Direct Cost: ¥30,500,000、Indirect Cost: ¥9,150,000)
Fiscal Year 2015: ¥40,040,000 (Direct Cost: ¥30,800,000、Indirect Cost: ¥9,240,000)
Fiscal Year 2014: ¥40,040,000 (Direct Cost: ¥30,800,000、Indirect Cost: ¥9,240,000)
Fiscal Year 2013: ¥38,870,000 (Direct Cost: ¥29,900,000、Indirect Cost: ¥8,970,000)
Fiscal Year 2012: ¥59,410,000 (Direct Cost: ¥45,700,000、Indirect Cost: ¥13,710,000)
|
|---|
| Outline of Final Research Achievements |
Bone has traditionally been regarded as a static structural organ that supports movement of the body and protects the internal organs. However, evidence has been accumulated in the past decade showing that bone also functions as an endocrine organ that regulates systemic glucose and energy metabolism. Osteocalcin (OC), an osteoblast-specific secreted protein, acts as a hormone by stimulating insulin production and increasing energy expenditure and insulin sensitivity in target organs. In the present study, we clarified that OC stimulated the secretion of glucagon-like peptide 1 from enteroendocrine cells, leading to insulin secretion. OC also stimulated adiponectin release from adipocytes. Thus, animal studies have shown that an oral application of OC ameliorates glucose intolerance, reducing blood glucose level. Therefore, it has been suggested that OC could be a feasible preventive or therapeutic agent for metabolic disorders.
|
